Gilead Sciences, Inc. - O-STA

Monday, Dec 30, 2024

14.11.2006 14:53
Gilead Sciences Successfully Completes Tender Offer for Shares of Myogen With Over 91.3 Percent of Shares Tendered
28.12.2005 08:34
Gilead to Repatriate Funds to the United States
28.06.2004 12:17
Gilead Sciences to be Added to S&P 500 Index
24.06.2004 08:26
Gilead Sciences to be Added to S&P 500 Index
08.06.2004 08:37
Gilead Sciences to Present at the 25th Annual Goldman Sachs Global Healthcare Conference on Tuesday June 8th; Webcast Available Through Gilead Corporate Website
18.05.2004 08:41
FDA Grants Priority Review to Gilead's Fixed Dose Co-Formulation of Viread and Emtriva for HIV;
04.05.2004 08:08
Gilead Sciences' Board Member Establishes Rule 10b5-1 Stock Trading Plan
28.04.2004 08:18
Gilead Sciences Announces New Commercial Structure and Changes to Senior Management Team; Expansion and Reorganization of Commercial Group to Support Anticipated Growth
23.04.2004 10:00
Gilead Sciences Announces First Quarter 2004 Financial Results; Total Revenues of $309 Million, Up 87 Percent over Firts Quarter 2003 Business
20.04.2004 14:49
Gilead Sciences Expands U.S. Patient Assistance Program to Help People Living With HIV Gain Faster Access to Therapy
16.04.2004 07:54
New Data Support Hepsera's Long-Term Efficacy against Chronic Hepatitis B
25.03.2004 19:00
Nicholas G. Moore Joins Gilead Sciences Board of Directors
15.03.2004 15:06
Gilead Submits Applications to U.S. and European Regulatory Authorities for Fixed Dose Co-Formulation of Viread and Emtriva
08.03.2004 14:41
Gilead Sciences to Present at the 24th Annual SG Cowen Healthcare Conference on Tuesday, March 9th; Webcast Available Through Gilead Corporate Website
05.03.2004 08:16
Gilead Sciences to Present at the 7th Annual Lehman Brothers Global Healthcare Conference on Friday, March 5th; Webcast Available Through Gilead Corporate Website
24.02.2004 14:43
6th Annual BIO CEO & Investor Conference
04.02.2004 14:15
Gilead Announces Data from Landmark Three-Year Clinical Trial of Viread; 144-Week Data Highlight Viread Efficacy, Safety and Side Effect Profile
30.01.2004 11:14
Gilead Sciences Announces Fourth Quarter and Full Year 2003 Financial Results
26.01.2004 08:07
Gilead Sciences to Release Fourth Quarter and Year-End 2003 Financial Results on Thursday, January 29, 2004; Conference Call and Webcast to Follow
12.01.2004 14:49
Gilead Files Investigational New Drug Application for Its Novel Protease Inhibitor; Anti-HIV Drug Developed Using Gilead's Proprietary Prodrug Technology Business
12.01.2004 09:19
Gilead Sciences to Present at the 22nd Annual JPMorgan Healthcare Conference on Monday